Two 10% owners of Aura Biosciences, Inc. (AURA) have divested significant holdings in the company. On May 7, 2026, David E. Goel and Capital Management Company, Lp Matrix each sold 6,922,870 shares, with the transactions occurring at a price of $5.64 per share. This resulted in total proceeds of approximately $39.04 million for each seller, bringing the combined value of the sales to nearly $78.09 million.
These sales by significant shareholders come on the heels of other insider selling activity earlier in April. While insider transactions can be motivated by a variety of factors such as portfolio diversification or personal financial planning, coordinated or substantial sales by multiple insiders can sometimes draw investor scrutiny.
Aura Biosciences, Inc. is a biotechnology company. The company's stock price has experienced fluctuations in recent trading sessions, against a backdrop of broader market sentiment in the healthcare sector.